In a nutshell This study evaluates the effectiveness of an immunotherapy in the treatment of newly diagnosed prostate cancer. The main outcome to be measured in this trial is the number of patients whose cancer does not progress within 3 years after immunotherapy injection. This trial is taking place in many sites across the USA. The details...
Read MoreIn a nutshell This trial is comparing the safety and effectiveness of venetoclax (Venclexta) and azacitidine (Vidaza) with azacitidine alone in patients with acute myeloid leukemia (AML). The main outcome to be measured will be overall survival. Complete remission (no signs of cancer after treatment) will also be measured. The details Acute...
Read MoreIn a nutshell This trial is comparing the effect of crenolanib with midostaurin (Rydapt) in the treatment of acute myeloid leukemia. The main outcome to be measured is event-free survival (EFS – survival time after treatment with cancer not coming back or getting worse). The details Acute myeloid leukemia (AML) is a cancer of the bone...
Read MoreIn a nutshell This study wanted to find out what benefits there were to doing electron radiation therapy during surgery alongside normal radiation therapy for women with breast cancer. The study found that ten years after surgery, almost all the patients who had electron radiotherapy during surgery had no reoccurrence of breast cancer. Some...
Read More
In a nutshell This study wanted to find out how the timing of radiation therapy affected survival in patients with lung cancer who underwent surgery. The study found that there was no difference in survival based on timing of radiation therapy. Some background There are a number of options for treatment of non-small cell lung cancer. Surgery...
Read More
In a nutshell This study wanted to find out which medications are better for treating advanced melanoma; nivolumab (Opdivo) plus ipilimumab (Yervoy), nivolumab alone, or ipilimumab alone. The study found that using the combination of nivolumab and ipilimumab was more effective than using nivolumab alone, with the least...
Read More
In a nutshell This study wanted to analyse which type of medication is best in treating lung cancer that may have spread to the brain. The study found that using erlotinib (Tarceva) is better than using gefitinib (Iressa) in preventing and treating tumors in the brain that have spread from the lung. Some background Epidermal growth factor receptor...
Read MoreIn a nutshell This study aimed to investigate the long-term effects of two treatment combinations for advanced prostate cancer. This study found that surgery and radiotherapy had improved overall survival in comparison with radiotherapy plus androgen deprivation therapy (ADT) in these patients, but with higher rates of side-effects. Some background...
Read More
In a nutshell This study evaluated the long-term safety and effectiveness of cryoablation (a process that uses extreme cold to destroy tissue) for patients with early prostate cancer. This study found that cryoablation is safe and effective for early-stage prostate cancer. Some background Cryoablation is a treatment option for early-stage prostate...
Read MoreIn a nutshell This study aimed to create a safe and effective low-intensity chemotherapy treatment plan for elderly patients with AML . This is an ongoing clinical trial and so far the authors have found the therapy has been safe and effective. Some background Outcomes for elderly patients with AML in the past have not been good due to the high...
Read More
In a nutshell This study evaluated the safety and effectiveness of the BR regimen (rituximab, bendamustine) in elderly patients with untreated low-tumor burden follicular lymphoma (LTBFL). This study concluded that the BR regimen may provide positive outcomes for these patients. Some background Low-tumor burden follicular lymphoma (LTBFL) is a type of...
Read MoreIn a nutshell This trial is examining the effectiveness of chemotherapy and atezolizumab (Tecentriq), given before surgery, for triple negative breast cancer. The main outcomes to be measured will be response in the breast tissue and lymph nodes and survival. The details Triple negative breast cancer is not dependent on the HER2 receptors or...
Read More
